International: +1-347-960-6455
Gastroenteritis Therapeutics - Pipeline Analysis 2018

Gastroenteritis Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

Report Code: PP10028 Report Type: Indication Pipeline Reports Available format: 
Therapeutic Area(s): Gastroenterology
Select License Type

Gastroenteritis, also known as infectious diarrhoea, is an inflammatory disease caused by bacteria, viruses, or parasites through contaminated food and water. The disease can be symptomatized by vomiting, nausea, cramping, and diarrhoea. Dehydration, joint inflammation, conjunctivitis, salmonella infection, persistent diarrhoea syndrome, lactose intolerance, and irritable bowel syndrome are among the several complications associated with gastroenteritis. The treatment medications for the disease include antimotility agents, antibiotics, rehydration, and antiemetics. Some of the non-infectious agents causing gastroenteritis are Crohn’s disease, celiac disease, and medications like nonsteroidal anti-inflammatory drugs. Vaxart Inc. is in the process of developing VXA-G1.1-NN, an oral vaccine for the treatment of norovirus gastroenteritis.

  • The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
  • Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.